Pacific Biosciences of California opened lower at $1.99, compared with its previous close of $2.09. In the last trading session, the stock traded between $1.80 and $2.06. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Pacific Biosciences of California is now worth
$ 7.32
Resulting in a loss of
$ 92.68 (92.68%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.12 (-5.50%)
Day High
$2.06
Day Low
$1.80
Day Open
$1.99
Prev Close
$2.09
Volume
97,93,123
1W Return
-22.97%
1M Return
-6.18%
3M Return
72.49%
6M Return
45.76%
1Y Return
6.18%
Market Cap ($ Mn)
618
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-389.62%
ROCE
-64.10%
EPS (TTM)
$-0.12
1 Week
-22.97%
1 Month
-6.18%
3 Months
72.49%
6 Months
45.76%
9 Months
7.34%
Pacific Biosciences enters $100M at-the-market equity sales agreement
Pacific Biosciences enters sales agreement with Allen & Co. Program allows selling up to $100 million in common stock. Utilizes at-the-market (ATM) equity offering structure. Disclosure filed with the Securities and Exchange Commission.
2 days agoPiper Sandler raises Pacific Biosciences price target to $3, keeps neutral
Piper Sandler raised the price target for Pacific Biosciences to $3. The rating remains Neutral as per analyst David Westenberg. Previous price target was set at $2 before the revision.
7 days agoPacific Biosciences Q3FY26 Results: Revenue rises 6% to $40.6 million
Total revenue rose 6% YoY to $40.6 million, driven by a 17% increase in instrument sales. Non-GAAP net loss narrowed to $32.8 million ($0.11/share) from $36.8 million in prior year. EMEA revenue surged 30% YoY to $14 million, offsetting flat Americas performance. Gross margin contracted to 36% from 42% due to memory costs and Vega transition expenses. Full-year revenue guidance narrowed to $155–$160 million; cash flow breakeven expected by 2028.
8 days agoPacific Biosciences cuts 8% of staff to save $30M-$40M annually
Pacific Biosciences Of California approved a restructuring plan on July 30, 2026, reducing its workforce by approximately 8% (40 employees) to align with strategic initiatives. The company expects to achieve annualized operating expense reductions of $30 million to $40 million by the end of 2027. Pre-tax charges for the reduction in force are estimated at $2 million, to be incurred in the third quarter of 2026.
3mo agoPacific Biosciences Cuts FY26 Sales Guidance Below Estimate
Pacific Biosciences lowers FY2026 sales guidance to $155.000M-$165.000M, missing the $166.790M estimate. The revision reduces the previous outlook of $165.000M-$175.000M, indicating weaker-than-expected demand.
3mo agoPacific Biosciences appoints Mark Van Oene as President and CEO
Pacific Biosciences of California appoints Mark Van Oene as President and CEO, effective August 5, 2026. Van Oene, formerly COO, succeeds Christian Henry, who steps down after six years but stays on the Board and as an advisor through 2026. Van Oene also joins the Board immediately.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Pacific Biosciences of California is now worth
$ 7.32
Resulting in a loss of
$ 92.68 (92.68%)
Note: Past profits do not guarantee future returns.
